RxDoctor Payments DataLook up a doctor →

Chad Meshberger, DO

Neurology · Concord, NHNPI 1306167424

Payments from drug & device makers

$9,503in general payments, 2019–2025

Across 572 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • UCB, Inc.$755
  • Teva Pharmaceuticals USA, Inc.$714
  • Amgen$635
  • Novartis$555
  • Sanofi$327
  • plus $5K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)90$1,213
UCB, Inc.57$755
Teva Pharmaceuticals USA, Inc.46$714
Amgen30$635
Novartis44$555
Sanofi16$327
Genentech USA, Inc.20$303
MDD US Operations, LLC16$301
Eisai Inc.11$294
Jazz Pharmaceuticals Inc.14$287
Biogen9$282
AstraZeneca(2 entities)11$225
SK Life Science, Inc.11$209
Lundbeck LLC9$199
Livanova USA, Inc.8$195
Johnson & Johnson(2 entities)8$175
Pfizer14$170
Neurocrine Biosciences, Inc.8$165
EMD Serono, Inc.8$151
Biohaven Pharmaceuticals, Inc.11$138
Sunovion Pharmaceuticals Inc.13$133
Lilly USA, LLC7$131
Acadia Pharmaceuticals Inc8$117
Xeris Pharmaceuticals, Inc.6$108
GRT US Holding, Inc.6$104
Upsher-smith Laboratories LLC5$90
Medtronic1$86
Acorda Therapeutics, Inc5$84
Avanir Pharmaceuticals, Inc.5$82
Averitas Pharma Inc.4$80
Grifols USA, LLC4$69
Gilead4$66
Aprecia Pharmaceuticals, LLC4$61
Scilex Pharmaceuticals Inc.3$58
Idorsia Pharmaceuticals US Inc3$55
Harmony Biosciences LLC2$50
Neurelis, Inc.3$49
Biohaven Pharmaceutical Holding Company Ltd.3$45
Supernus Pharmaceuticals, Inc.3$43
Tanabe Pharma America, Inc.3$43
Ipsen Biopharmaceuticals, Inc2$41
Almatica Pharma LLC2$40
Currax Pharmaceuticals LLC3$37
Mallinckrodt Hospital Products Inc.2$37
CSL Behring2$33
Impel Pharmaceuticals Inc.2$31
Sumitomo Pharma America, Inc.2$29
Amneal Pharmaceuticals LLC2$29
Valeritas, Inc.2$29
180 Medical, Inc.1$25
Bausch Health US, LLC1$24
Bristol Myers Squibb1$24
Takeda Pharmaceuticals U.S.A., Inc.1$23
Argenx US, Inc.1$22
Banner Life Sciences, LLC1$21
Sanofi-aventis U.S. LLC1$20
Otsuka America Pharmaceutical, Inc.1$19
Merck1$18
TG Therapeutics, Inc.1$18
Abbott1$16

How this compares

$9,503 in reported general payments places this provider in the 80th percentile of 92 neurology providers in New Hampshire.

See all neurology providers in New Hampshire →

Medicare billing

Part B allowed, 2024
$80,483
Medicare patients
171
Services billed
13,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Concord

See the full list for New Hampshire →

Where these figures come from

Is this you, or does something look wrong? →